AAA
AKBA icon

Affinity Asset Advisors’s Akebia Therapeutics AKBA Stock Holding History

Affinity Asset Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,450,000
Closed -$6.69M – 96
2025
Q3 		$6.69M Buy
2,450,000
+500,000
+26% +$1.66M 0.58% 45
2025
Q2 		$7.1M Buy
1,950,000
+450,000
+30% +$1.24M 0.97% 30
2025
Q1 		$2.88M Buy
+1,500,000
New +$3.06M 0.27% 56

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Affinity Asset Advisors's AKBA Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 2,450,000 shares — an estimated $6.69M sold.

Affinity Asset Advisors first reported a position in AKBA in Q1 2025 and held it in 3 quarters. The position peaked at $7.1M in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 2,450,000 Akebia Therapeutics shares in Q4 2025, an estimated $6.69M.
  • Affinity Asset Advisors first reported a position in Akebia Therapeutics in Q1 2025 and held it in 3 quarters.
  • Affinity Asset Advisors's Akebia Therapeutics position peaked at $7.1M in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.